Natera shares surge 17% after strong Q2 results and upgraded guidance

Natera (NTRA) shares surged 17% after reporting strong Q2 2025 results, with revenue increasing 32.2% to $546.6 million, exceeding Wall Street expectations. Despite a wider GAAP loss per share of $0.74, the company significantly raised its full-year 2025 revenue guidance to a $2.06 billion midpoint, signaling management's confidence in its growth trajectory. This top-line performance and optimistic outlook led RBC Capital to raise Natera's price target to $255, reinforcing its position as a top pick in the liquid biopsy sector despite its current unprofitability.

Analysis

Natera (NTRA) delivered a strong operational performance in its Q2 2025 results, triggering a significant positive market reaction with shares surging as much as 17% intraday. The company's revenue grew 32.2% year-over-year to $546.6 million, comfortably beating Wall Street estimates, driven by a 12.7% increase in test volumes and notable strength in its Signatera oncology testing platform. While the company reported a wider-than-expected GAAP loss per share of $0.74 against a $0.62 consensus, investors prioritized the firm's growth trajectory and forward-looking commentary. This sentiment was bolstered by management raising its full-year 2025 revenue guidance to a midpoint of $2.06 billion, an $80 million increase that sits 4% above analyst expectations. The results prompted a bullish response from RBC Capital, which reiterated its 'Outperform' rating and raised its price target to $255, citing Natera's position as a top-tier liquid biopsy play with strong fundamentals, including a 61.79% gross profit margin and a current ratio of 3.87. The market's willingness to overlook near-term unprofitability in favor of accelerating top-line growth underscores confidence in Natera's long-term strategy and market leadership.

Key Decisions for Investors

• Investors should weigh the compelling top-line growth and substantially raised guidance against the persistent unprofitability, as the market is clearly prioritizing revenue momentum over near-term earnings.
• Monitor the performance of the Signatera platform, as its record growth was cited as a key driver and is central to the bull thesis presented by analysts like RBC Capital.
• Given the strong analyst consensus and the price target increase to $255, investors may see the post-earnings level as a new base, but should remain aware that continued share price appreciation is highly dependent on the company meeting or exceeding its new, higher growth expectations.